Keith W. Marshall - 16 Dec 2022 Form 4 Insider Report for Prometheus Biosciences, Inc.

Role
Chief Financial Officer
Signature
/s/ Timothy K. Andrews, attorney-in-fact for Keith W. Marshall
Issuer symbol
N/A
Transactions as of
16 Dec 2022
Net transactions value
$0
Form type
4
Filing time
20 Dec 2022, 19:19:24 UTC
Previous filing
13 Dec 2022
Next filing
19 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Option (Right to Buy) Award $0 +12,920 $0.000000 12,920 16 Dec 2022 Common Stock 12,920 $108.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option will vest on December 16, 2023, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.